Zacks Investment Research·Sep 4, 2026
Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?MED is shifting toward metabolic health with its 3.0 strategy, targeting broader growth, greater efficiency and a return to profitability.
Medifast faces an existential threat as its OPTAVIA coaching model experiences a 34.3% year-over-year revenue decline, likely driven by the rise of pharmaceutical weight-loss alternatives. While the company maintains a robust 68.1% gross margin and a conservat...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | -$0.28+56.9% vs -$0.65 | $76M+5.1% vs $73M |
Q2 2026 May 4, 2026 | -$0.19+65.5% vs -$0.55 | $76M+9.9% vs $69M |
Q1 2026 Feb 17, 2026 | -$0.55+27.6% vs -$0.76 | $75M+5.2% vs $71M |
Q4 2025 Nov 3, 2025 | -$0.21-2000.0% vs -$0.01 | $89M+25.2% vs $71M |
MED is shifting toward metabolic health with its 3.0 strategy, targeting broader growth, greater efficiency and a return to profitability.
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) has announced the launch of the Medifast Metabolic Health Institute, established to advance metabolic health through rigorous research and credible, evidence-based education. The institute brings Medifast's clinical research, scientific expertise, and educational resources under a single body, solidifying the company's position in the metabolic health space. It follows the July launch of Trilivy™, which replaced OPTAVIA® as the company's co.
Benchmark MED against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Medifast, Inc. (MED)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.95 | $132.87M | -7.03 | -35.96% | -4.84% | -9.13% | 0.15% | |
| $28.39 | $6.33B | 55.67 | 59% | -5.51% | -30.03% | — | |
| $4.61 | $223.82M | 1.45 | -14.26% | -15.73% | -29.42% | — | |
| $14.04 | $259.22M | 24.21 | 8.28% | -2.43% | -3.8% | — | |
| $20.72 | $1.48B | 24.09 | 8.48% | 5.54% | 14.03% | — | |
| $15.03 | $150.28M | 0.14 | -9.58% | -14.78% | -33.75% | — |
Medifast, Inc. (MED) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Medifast, Inc. (MED) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jul 17, 2026·SEC
Jun 1, 2026·SEC
Get notified when MED posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Medifast, Inc. (MED) stock FAQ — growth, dividends, profitability & financials explained
Medifast, Inc. (MED) reported $316.9M in revenue for fiscal year 2025. This represents a 1820% increase from $16.5M in 1996.
Medifast, Inc. (MED) saw revenue decline by 36.0% over the past year.
Medifast, Inc. (MED) reported a net loss of $25.6M for fiscal year 2025.
Yes, Medifast, Inc. (MED) pays a dividend with a yield of 0.15%. This makes it attractive for income-focused investors.
Medifast, Inc. (MED) has a return on equity (ROE) of -9.1%. Negative ROE indicates the company is unprofitable.
Medifast, Inc. (MED) generated $4.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
